The Predictive Role of Neurobiochemical Markers in Multiple Sclerosis

Basit Öğe Kaydı
dc.authoridMungan, Semra/0000-0002-6469-5185
dc.authoridFirat Oguz, Esra/0000-0002-8147-5379
dc.contributor.authorOguz, Esra Firat
dc.contributor.authorMungan, Semra
dc.contributor.authorYilmaz, Fatma Meric
dc.contributor.authorErcan, Mujgan
dc.contributor.authorUysal, Sema
dc.date.accessioned2025-01-27T20:20:21Z
dc.date.available2025-01-27T20:20:21Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Multiple sclerosis (MS) is the most common, chronic, inflammatory, demyelinating disease of the central nervous system. We aimed to evaluate the levels of some neurobiochemical markers in order to evaluate their predictive role in MS. Methods: Fifty-one patients with a diagnosis of MS and 37 healthy subjects were included in the study. The patients with MS were diagnosed by a skilled neurologist based on the medical history and physical examination according to revised McDonald criteria. Neuron-specific enolase (NSE) and S100B levels were measured by electrochemiluminescence immunoassay. Glial fibrillary acidic protein (GFAP) and myelin basic protein (MBP) were measured by quantitive sandwich enzyme immunoassay technique with a commercially available ELISA kit. Results: There was a significant difference in NSE levels between the patient and the control groups. No significant difference was determined between the patient and the control groups in terms of S10013, MBP, and GFAP levels. S100B levels were positively correlated with Expanded Disability Status scale scores. Conclusion: Our findings indicated that NSE levels are significantly lower in MS patients. However, NSE levels should not be used alone at discriminating the disease. Multifactorial evaluation should be done during the diagnosis and follow-up of MS.
dc.description.sponsorshipAnkara Numune Training and Researc Hospital [63424/01/2013]
dc.description.sponsorshipThis study was funded by Ankara Numune Training and Researc Hospital Scientific Research Support Budget (63424/01/2013).
dc.identifier.doi10.4274/imj.galenos.2019.75002
dc.identifier.endpage27
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue1
dc.identifier.startpage23
dc.identifier.trdizinid360811
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2019.75002
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/360811
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21677
dc.identifier.volume21
dc.identifier.wosWOS:000512371600006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Training & Research Hospital
dc.relation.ispartofIstanbul Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectMultiple sclerosis
dc.subjectGFAP
dc.subjectMBP
dc.subjectNSE
dc.subjectS100B
dc.titleThe Predictive Role of Neurobiochemical Markers in Multiple Sclerosis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu